Director/Senior Director, Total Rewards at Schrödinger

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Life Sciences, Drug Discovery, Materials ScienceIndustries

Requirements

At least eight years of progressive experience in compensation and benefits, including at least five in a leadership role or an equivalent
Expertise in designing and scaling global compensation frameworks, incentive plans, and equity programs
Deep understanding of US and international benefits regulations and practices
Experience with compensation analytics tools, HRIS platforms, and market survey data (e.g., Aon, Radford, Mercer)
Excellent communication, presentation, and stakeholder management skills
Master’s degree and/or certifications in Human Resources, Business, or a related field (preferred)
Willingness to travel quarterly

Responsibilities

Lead compensation strategy by designing, implementing, and continuously refining global compensation philosophy and structures, including salary bands, incentive plans, and equity programs
Oversee benefits programs by evaluating, implementing, and managing competitive benefits offerings (healthcare, retirement, wellness, and perks) to support employee well-being across all regions
Lead salary review cycles, bonus planning and management, and equity grants, ensuring alignment with budget and business objectives
Conduct benchmarking, surveys, and market analyses to keep compensation packages competitive and compliant
Stay current on compensation and benefits regulations (FLSA, ERISA, GDPR, etc.) and ensure programs are legally compliant
Optimize People systems and analytics to track compensation data, identify trends, and inform decision-making
Manage and mentor a small team
Advise executives and managers on pay decisions, policy interpretation, and job leveling to ensure fairness and consistency; collaborate across the People Team and with Finance to provide guidance on compensation-related business problems

Skills

Compensation Strategy

Benefits Management

Market Benchmarking

Equity Programs

Incentive Plans

Salary Bands

Global Rewards

Data Analysis

HR Leadership

Wellness Programs

Retirement Plans

Healthcare Benefits

Schrödinger

Computational platform for biopharmaceutical research

About Schrödinger

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by using sophisticated algorithms and simulations to predict how different compounds will interact, which can significantly speed up the research process. Unlike many competitors, Schrödinger not only licenses its software but also engages in collaborative research and drug discovery programs, allowing for a more integrated approach to scientific research. The company's goal is to enhance scientific research and development through its platform, ultimately leading to the discovery of new drugs and therapies.

New York City, New YorkHeadquarters

1990Year Founded

$362.7MTotal Funding

IPOCompany Stage

Government & Public Sector, Enterprise Software, BiotechnologyIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Paid Vacation

Parental Leave

Risks

Recursion and Exscientia merger creates strong AI-driven drug discovery competitor.

Avicenna's independent expansion could lead to competitive tensions with Schrödinger.

High R&D costs may strain resources despite Gates Foundation's $10M grant.

Differentiation

Schrödinger's platform supports diverse clients, including biopharma, academia, and government labs.

The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.

Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.

Upsides

$19.5M Gates Foundation grant boosts platform for neglected diseases, expanding market reach.

Predictive toxicology tools initiative could lead to safer, efficient drug development.

SGR-1505 discovery showcases ability to reduce drug discovery timelines significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free